NZ599439A - Compositions and methods for treating centrally mediated nausea and vomiting - Google Patents

Compositions and methods for treating centrally mediated nausea and vomiting

Info

Publication number
NZ599439A
NZ599439A NZ599439A NZ59943910A NZ599439A NZ 599439 A NZ599439 A NZ 599439A NZ 599439 A NZ599439 A NZ 599439A NZ 59943910 A NZ59943910 A NZ 59943910A NZ 599439 A NZ599439 A NZ 599439A
Authority
NZ
New Zealand
Prior art keywords
compositions
vomiting
methods
treating
centrally mediated
Prior art date
Application number
NZ599439A
Other languages
English (en)
Inventor
Fabio Trento
Sergio Cantoreggi
Giorgia Rossi
Roberta Cannella
Daniele Bonadeo
Riccardo Braglia
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ599439(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of NZ599439A publication Critical patent/NZ599439A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Paints Or Removers (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
NZ599439A 2009-11-18 2010-11-18 Compositions and methods for treating centrally mediated nausea and vomiting NZ599439A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26247009P 2009-11-18 2009-11-18
US38270910P 2010-09-14 2010-09-14
PCT/IB2010/003106 WO2011061622A1 (en) 2009-11-18 2010-11-18 Compositions for treating centrally mediated nausea and vomiting

Publications (1)

Publication Number Publication Date
NZ599439A true NZ599439A (en) 2014-06-27

Family

ID=43608757

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ599439A NZ599439A (en) 2009-11-18 2010-11-18 Compositions and methods for treating centrally mediated nausea and vomiting

Country Status (40)

Country Link
US (1) US12042494B2 (enExample)
EP (3) EP2722044B1 (enExample)
JP (1) JP5890780B2 (enExample)
KR (1) KR101615108B1 (enExample)
CN (6) CN107050455B (enExample)
AP (1) AP3083A (enExample)
AU (1) AU2010320598B2 (enExample)
BR (1) BR112012011485B1 (enExample)
CA (1) CA2778301C (enExample)
CL (1) CL2012001276A1 (enExample)
CO (1) CO6551693A2 (enExample)
CR (1) CR20120216A (enExample)
CU (1) CU24048B1 (enExample)
CY (1) CY1118062T1 (enExample)
DK (2) DK2722045T3 (enExample)
DO (1) DOP2012000138A (enExample)
EA (1) EA026815B1 (enExample)
EC (1) ECSP12011907A (enExample)
ES (4) ES2559475T3 (enExample)
GE (1) GEP20156226B (enExample)
GT (1) GT201200156A (enExample)
HK (2) HK1214147A1 (enExample)
HR (3) HRP20140759T1 (enExample)
HU (1) HUE029677T2 (enExample)
IL (1) IL219576A (enExample)
LT (1) LT2722045T (enExample)
MA (1) MA33810B1 (enExample)
MX (1) MX2012005347A (enExample)
MY (1) MY159393A (enExample)
NI (1) NI201200090A (enExample)
NZ (1) NZ599439A (enExample)
PE (1) PE20121483A1 (enExample)
PH (1) PH12012500887A1 (enExample)
PL (3) PL2722044T3 (enExample)
PT (2) PT2722045T (enExample)
RS (2) RS53491B1 (enExample)
SI (2) SI2722045T1 (enExample)
SM (1) SMT201400112B (enExample)
TN (1) TN2012000170A1 (enExample)
WO (1) WO2011061622A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
PE20121483A1 (es) 2009-11-18 2012-12-02 Helsinn Healthcare Sa Composiciones para tratar nausea y vomito centralmente mediados
WO2013004766A1 (en) * 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
WO2013057554A2 (en) * 2011-10-18 2013-04-25 Helsinn Healthcare Sa Therapeutic combinations of netupitant and palonosetron
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
CN103520725B (zh) * 2012-07-05 2017-10-24 海思科医药集团股份有限公司 一种治疗呕吐的药物组合物
RU2770050C2 (ru) 2015-03-04 2022-04-14 Ванда Фармасьютиклз Инк. Способ лечения с применением традипитанта
CN106902086B (zh) * 2015-12-23 2020-10-20 江苏恒瑞医药股份有限公司 一种包含奈妥匹坦的固体组合物
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN108721214B (zh) * 2017-04-14 2020-06-16 和龙 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
CN108853010A (zh) * 2017-05-15 2018-11-23 和龙 奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
CN109200018A (zh) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 含有奈妥吡坦的微乳制剂
DK3710000T3 (da) * 2017-11-17 2025-06-16 Vanda Pharmaceuticals Inc Tradipitant til anvendelse til behandling af gastroparese
WO2019148247A1 (en) * 2018-02-02 2019-08-08 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Oral formulations and uses thereof
JP2024501994A (ja) * 2020-12-25 2024-01-17 上海盛迪医▲葯▼有限公司 Ｎｋ１拮抗剤プロドラッグ化合物と５－ｈｔ３受容体拮抗剤との併用使用
EP4385500B1 (en) 2022-12-12 2026-07-01 Alfred E. Tiefenbacher (GmbH & Co. KG) FIXED-DOSE COMBINATION INCLUDING NETUPITANT AND PALONOSETRON
AU2023393578A1 (en) 2022-12-12 2025-07-03 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Fixed dose combination comprising netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4633608A1 (en) * 2022-12-12 2025-10-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
WO2025246530A1 (en) * 2024-05-30 2025-12-04 The Chinese University Of Hong Kong Personalized anti-emetic treatment for chemotherapy-induced nausea and vomiting

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU642178B2 (en) 1989-11-28 1993-10-14 Roche Palo Alto Llc New tricyclic compounds
US5510486A (en) 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US6297395B1 (en) 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
PT1303490E (pt) 2000-07-14 2008-09-04 Hoffmann La Roche Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina
DK1349541T3 (da) 2000-12-14 2007-01-08 Hoffmann La Roche Selvemulgerende lipidmatrix (SELM)
JP5690461B2 (ja) 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
JP2006522817A (ja) * 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
US7479312B2 (en) 2005-07-07 2009-01-20 Konica Minolta Opto, Inc. Retardation film, polarizing plate, and liquid crystal display device
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AU2007219236B2 (en) * 2006-02-23 2012-06-21 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
EA016455B1 (ru) * 2006-10-24 2012-05-30 Хелсинн Хелткэр С.А. Мягкие капсулы, содержащие палоносетрона гидрохлорид, имеющие улучшенную стабильность и биологическую доступность
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
EP2247757A2 (en) * 2007-12-18 2010-11-10 Schering Corporation Biomarkers for sensitivity to anti-igf1r therapy
PE20121483A1 (es) 2009-11-18 2012-12-02 Helsinn Healthcare Sa Composiciones para tratar nausea y vomito centralmente mediados

Also Published As

Publication number Publication date
AP3083A (en) 2015-01-31
US20230263799A1 (en) 2023-08-24
CA2778301A1 (en) 2011-05-26
PE20121483A1 (es) 2012-12-02
CN107050455B (zh) 2020-09-29
HUE029677T2 (hu) 2017-03-28
BR112012011485B1 (pt) 2021-06-29
EP2361090A1 (en) 2011-08-31
EP2722044A1 (en) 2014-04-23
CN106512010A (zh) 2017-03-22
ES2623503T3 (es) 2017-07-11
NI201200090A (es) 2012-11-13
CR20120216A (es) 2012-07-24
TN2012000170A1 (en) 2013-12-12
PL2722045T3 (pl) 2017-03-31
EP2722044B1 (en) 2017-01-04
BR112012011485A2 (pt) 2018-04-03
CN102655864A (zh) 2012-09-05
KR20120101456A (ko) 2012-09-13
CU20120078A7 (es) 2012-10-15
CU24048B1 (es) 2014-12-26
ES2595077T3 (es) 2016-12-27
JP5890780B2 (ja) 2016-03-22
HRP20140759T1 (hr) 2014-10-24
PL2722044T3 (pl) 2017-08-31
CN107050455A (zh) 2017-08-18
CA2778301C (en) 2016-06-14
DK2722045T3 (en) 2016-10-24
EA026815B1 (ru) 2017-05-31
DOP2012000138A (es) 2012-11-15
CL2012001276A1 (es) 2012-12-07
SMT201400112B (it) 2014-11-10
ES2559475T3 (es) 2016-02-12
MY159393A (en) 2016-12-30
IL219576A (en) 2017-08-31
RS53491B1 (sr) 2015-02-27
GT201200156A (es) 2014-03-27
EP2727590A1 (en) 2014-05-07
LT2722045T (lt) 2016-09-26
WO2011061622A1 (en) 2011-05-26
CN104856998A (zh) 2015-08-26
CN106421793B (zh) 2023-06-16
AP2012006278A0 (en) 2012-06-30
HK1214147A1 (zh) 2016-07-22
US12042494B2 (en) 2024-07-23
SI2722045T1 (sl) 2017-02-28
PT2361090E (pt) 2014-09-03
IL219576A0 (en) 2012-06-28
PH12012500887A1 (en) 2016-08-26
SI2361090T1 (sl) 2014-09-30
JP2013511507A (ja) 2013-04-04
CO6551693A2 (es) 2012-10-31
CN106421793A (zh) 2017-02-22
DK2361090T3 (da) 2014-08-25
KR101615108B1 (ko) 2016-05-12
CN104856999A (zh) 2015-08-26
ES2494015T3 (es) 2014-09-12
PT2722045T (pt) 2016-10-18
GEP20156226B (en) 2015-01-26
HRP20170419T1 (hr) 2017-06-02
MA33810B1 (fr) 2012-12-03
ECSP12011907A (es) 2012-10-30
EP2361090B1 (en) 2014-05-21
RS55206B1 (sr) 2017-01-31
CY1118062T1 (el) 2017-06-28
HRP20161277T1 (hr) 2016-11-18
MX2012005347A (es) 2012-08-03
HK1214148A1 (zh) 2016-07-22
PL2361090T3 (pl) 2014-10-31
EP2727590B1 (en) 2015-10-21
AU2010320598B2 (en) 2016-06-16
EA201290356A1 (ru) 2012-12-28
AU2010320598A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
UA97653C2 (ru) Мягкие капсулы, содержащие палоносетрона гидрохлорид, которые имеют улучшенную стабильность и биологическую доступность
IN2012DN02735A (enExample)
IN2012DN02702A (enExample)
IN2012DN00754A (enExample)
JO3078B1 (ar) مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
WO2011091305A3 (en) Inhibition of axl signaling in anti-metastatic therapy
MX2010009447A (es) Uso de antagonistas de lhrh a dosis no castrantes.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
EA201270617A2 (ru) Способы лечения или предотвращения тромбоза стента
MX345656B (es) (piridin-4-il)bencilamidas como moduladores alostericos de nachr alfa 7.
GEP20146103B (en) Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
MX2018000546A (es) Composiciones farmaceuticas que contienen celecoxib y tramadol.
MX2012002681A (es) Agente terapeutico/profilactico que contiene pth para la osteoporosis, caracterizado porque la pth se administra una vez a la semana en una dosis unitaria de 100 a 200 unidades.
MA32384B1 (fr) Association pharmacologique
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
EA201491831A1 (ru) Содержащие прасугрель стабильные фармацевтические композиции с немедленным высвобождением для перорального введения
PH12018500814A1 (en) Oxadiazaspiro compounds for the treatment of drug abuse and addiction
IN2014DN09437A (enExample)
MX358211B (es) Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
ZA201500410B (en) Formulations for the preparation of immediate-release tablets for oral use containing low-dose mifepristone for the treatment of endometriosis, tablets thus obtained and their preparation process
BR112012020415A2 (pt) composição farmacêutica para a prevenção ou tratamento da osteoartrite
UA109944U (uk) Фармацевтична композиція для зниження рівня n-оксиду триметиламіну

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2015 BY ANAQUA SERVICES

Effective date: 20141023

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2016 BY ANAQUA SERVICES

Effective date: 20151022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2017 BY ANAQUA SERVICES

Effective date: 20161020

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2018 BY ANAQUA SERVICES

Effective date: 20171019

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2019 BY ANAQUA SERVICES

Effective date: 20181026

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2020 BY ANAQUA SERVICES

Effective date: 20191022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2021 BY ANAQUA SERVICES

Effective date: 20201020

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2022 BY ANAQUA SERVICES

Effective date: 20211020

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2023 BY ANAQUA SERVICES

Effective date: 20221022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2024 BY ANAQUA SERVICES

Effective date: 20231020

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2025 BY ANAQUA SERVICES

Effective date: 20241022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2026 BY ANAQUA SERVICES

Effective date: 20251022